Dako Gets FDA OK for HER2 Tests for Gastric, Stomach Cancer

The Danish firm received FDA clearance to expand the intended use of its HercepTest and HER2 FISH pharmDx Kit to include patients with metastatic gastric or stomach cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.